RNA Outsourcing Resources

1. Guidelines To Bring Your Drug To Market: Are You Prepared? 4/16/2019

   Are you up to the task of bringing a biologic drug to market? Do you have a strategy and plan for moving forward? Here, we explore this from a biopharma process development and manufacturing perspective.

2. 5 Outdated Practices Holding Back Modern Bioanalysis 10/20/2025

   Bioanalysis must replace outdated paper, manual processes, and disjointed systems with integrated, automated platforms for continuous validation, efficiency, compliance, and to support complex modern therapies.

3. Shifting The Approach: 4 Tactics For ICH E6(R3) Implementation 4/30/2024

   In addition to codifying some best practices, R3 recommends that sponsors adopt an approach to identifying and managing areas of risk to mitigate potential issues and enhance overall success.

4. How To Unlock The Secret To Repeatable, Scalable Low Turnover 6/7/2024

   Here, we explore the evolution of a 10-year partnership and extrapolate the principles that create cohesive teams and minimize turnover.

5. 5 Key Considerations For Companies Outsourcing Process Development 6/9/2025

   Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.

6. How To Choose The Right CRO For Your Clinical Trial 3/28/2025

   Selecting the right Contract Research Organization (CRO) is critical for the success of a clinical trial. This article outlines essential factors to consider during the selection process.

7. Improving Toxicology Testing For Inhalation Products 1/22/2024

   By embracing new approach methods, regulatory agencies can revolutionize toxicology testing. These methods can be adapted for various medications, including inhalers and nasal-administered drugs.

8. Improvement Of Self-Amplifying RNA Quality And Potency With IVT Optimization 1/28/2025

   Explore our study on optimizing In-Vitro Transcription (IVT) conditions for self-amplifying RNAs to achieve high yields, low residual dsRNA, and improved potency, and learn how these advancements can enhance RNA-based therapies.

9. Is Not Using A CDMO Slowing Down Your Process Development? 4/27/2020

   Consider what process development capabilities you have versus what you could possibly gain from working with a CDMO to not only be successful but also improve your chances of getting to market sooner.

10. Optimizing qPCR For Broad-Range Transcript Detection In Anti-PD-1 Therapy 4/23/2025

    Optimize qPCR protocols for greater sensitivity and reproducibility to accurately measure immune-related gene expression and better identify patients who will benefit from anti-PD-1 immunotherapy.